+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The use of oral anticoagulants for the treatment of venous thromboembolic events in an ED

The use of oral anticoagulants for the treatment of venous thromboembolic events in an ED

American Journal of Emergency Medicine 32(12): 1526-1533

Venous thromboembolism (VTE) is a disease spectrum that ranges from deep vein thrombosis (DVT) to pulmonary embolism (PE). Rapid diagnosis and treatment of VTE by emergency care providers are critical for decreasing patient mortality, morbidity, and the incidence of recurrent events. Recent American College of Chest Physicians guidelines recommend initial treatment with unfractionated heparin, low-molecular weight heparin, or fondaparinux overlapped with warfarin for a minimum of 5 days for the treatment of VTE in most cases. Warfarin monotherapy is thereafter continued for 3, 6, or 12 months. These guidelines were published before the approval of target-specific oral anticoagulants (TSOACs), and they have yet to be updated to reflect these new treatment options. For some patients, TSOACs, which act by directly inhibiting factor IIa or factor Xa, may provide safer, more convenient alternatives to warfarin. Their advantages include ease of use, reduced monitoring requirements, and lower bleeding risk than traditional therapy. Additionally, clinical trials have established noninferiority of TSOACs to warfarin for the prevention of recurrent VTE. These trials have demonstrated that TSOACs exhibit similar or lower bleeding rates, particularly intracranial bleeding rates compared with warfarin. Anticoagulation therapy with TSOACs may allow early discharge or outpatient management options for low-risk patients with DVT and PE. This review addresses the importance of early diagnosis and treatment of VTE, outcomes of VTE risk assessment, key efficacy and safety data from phase 3 clinical trials for the various TSOACs for the treatment of DVT and PE, and the corresponding considerations for clinical practice.

(PDF emailed within 0-6 h: $19.90)

Accession: 056527054

Download citation: RISBibTeXText

PMID: 25315880

DOI: 10.1016/j.ajem.2014.08.075

Related references

New oral anticoagulants in the treatment of venous thromboembolic disease. Semergen 39(3): 146-149, 2013

Direct Oral Anticoagulants in the Treatment of Venous Thromboembolic Disease. Annals of Vascular Surgery 42: 337-350, 2017

Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i Sosudistaia Khirurgiia 23(2): 82-87, 2017

Extended anticoagulant treatment of venous thromboembolic disease with direct oral anticoagulants. Semergen 44(7): 500-503, 2018

Hemorrhagic and thromboembolic complications versus intensity of treatment of venous thromboembolism with oral anticoagulants. Acta Medica Scandinavica 224(5): 425-430, 1988

Impact of an education program on patient behaviour favoring prevention of drug-related adverse events: a pilot study in patients receiving oral anticoagulants for thromboembolic venous disease. Journal des Maladies Vasculaires 29(3): 152-158, 2004

New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Therapeutics and Clinical Risk Management 11: 967-977, 2015

A Cost-Effectiveness Analysis Of Novel Oral Anticoagulants For Acute Treatment And Secondary Prevention Of Venous Thromboembolic Disease. Value in Health 18(7): A390-A390, 2015

Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. Expert Opinion on PharmacoTherapy 17(15): 2033-2047, 2016

Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. Journal of the American College of Cardiology 72(16): 1984-1986, 2018

Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study. British Journal of Clinical Pharmacology: -, 2018

New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation: an appraisal. Journal of Hypertension 35(4): 689-695, 2016

Economic evaluation of the new oral anticoagulants for the prevention of thromboembolic events: a cost-minimization analysis. Sao Paulo Medical Journal 134(4): 322-329, 2016

A Cost-Effectiveness Analysis of Novel Oral Anticoagulants for Primary Prevention of Venous Thromboembolic Disease. Value in Health 18(7): A339-A340, 2015

Anticoagulants for prophylaxis and treatment of thromboembolic events. Blood 99(6): 2279-2280, 2002